AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...

AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stages of its trials. The ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...

Confidence in the company rose as shares for both AbbVie and its parent company, Abbott Laboratories, increased on the first day of trading in the New Year. AbbVie's stock opened yesterday at US $ ...

Here's my favorite Dividend King to buy in November. AbbVie, therefore, inherits the rich dividend history of its parent. In September, Abbott announced its 52nd consecutive annual dividend increase.

CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...

AbbVie shares fell over 12% on Monday after ... Alzheimer's drug from Eisai and Biogen rejected in Europe Abbott Laboratories raised its annual profit forecast on Thursday after its second-quarter ...